PYC Therapeutics

9 OCTOBER 2025

ADOA PROGRAM: SAFETY REVIEW OUTCOME ENABLES PROGRESSION INTO MULTI-DOSE STUDY

- **PYC is progressing an investigational drug candidate (known as PYC-001) that addresses the underlying cause of a blinding eye disease called Autosomal Dominant Optic Atrophy (ADOA) through clinical trials**
- **The Company today announces that the Safety Review Committee (SRC) governing the Phase 1 Single Ascending Dose (SAD) study of PYC-001 has reviewed the 4-week safety/tolerability outcomes for ADOA patients in cohort 3 of the SAD (30 microgram dose of PYC-001) and confirmed that there are no safety concerns following a single dose of PYC-001 at all three doses evaluated in the SAD study[1]**
- **PYC is now progressing PYC-001 into a global Phase 1/2 MAD study that is anticipated to commence in Q4 2025[2]**

PERTH, Australia and SAN FRANCISCO, California – 9 October 2025

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.

The Company currently has three clinical-stage drug development programs including an investigational drug candidate (known as PYC-001) that addresses the underlying cause of a blinding eye disease called Autosomal Dominant Optic Atrophy (ADOA). ADOA affects 1 in every 35,000[3] people and there are currently no approved treatment options available for patients with ADOA.

PYC today announces that the Safety Review Committee (SRC) monitoring the Single Ascending Dose (SAD) study has reviewed the 4-week safety/tolerability data for the third and final patient cohort in the SAD study and has confirmed that there are no safety concerns in any of the three doses (3, 10 and 30 micrograms per eye) assessed in this study[4].

[1] Through 4 weeks of follow up
[2] Subject to the risks and uncertainties outlined in the Company's ASX filings of 17 February 2025 including receiving regulatory and human ethics approval to do so
[3] Yu-Wai-Man, P. et al. The Prevalence and Natural History of Dominant Optic Atrophy Due to OPA1 Mutations Ophthalmology. 2010;117(8):1538-46 doi: 10.1016/j.ophtha.2009.12.038
[4] Through 4 weeks of follow up

Figure 1. Proposed clinical development pathway for PYC-001 in ADOA[5]



Next Steps

Based on the outcome of the SAD study, PYC is now preparing to progress into a global Multiple Ascending Dose (MAD) study of PYC-001 in patients with ADOA with an objective of establishing clinical proof-of-concept prior to progression into a global registrational trial directed towards supporting a New Drug Application for PYC-001 in ADOA. The global Phase 1/2 MAD study is expected to commence in Q4 of 2025[6].

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development[7].

For more information, visit pyctx.com, or follow us on LinkedIn and X.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans,

[5] Subject to regulatory approval
[6] Subject to regulatory and human ethics approval
[7] Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank https://doi.org/10.1101/2020.11.02.20222232

expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACT US

Investor relations and media contact
investor@pyctx.com